Molnar D, La EM, Verelst F, Poston S, Graham J, Van Bellinghen LA, Curran D. Public health impact of the adjuvanted RSVPreF3 vaccine for respiratory syncytial virus prevention among older adults in the United States. Infect Dis Ther. 2024 Mar 20. doi: 10.1007/s40121-024-00939-w
Wilson M, McDade C, Beby-Heijtel AT, Waterval-Overbeek A, Sundaram V, Perdrizet J. Assessing public health impact of five pediatric pneumococcal conjugate vaccination strategies in the Netherlands. Infect Dis Ther. 2023 Jul;12(7):1809-21. doi: 10.1007/s40121-023-00828-8
Perdrizet J, Horn EK, Hayford K, Grant L, Barry R, Huang L, McDade C, Wilson M. Historical population-level impact of infant 13-valent pneumococcal conjugate vaccine (PCV13) national immunization programs on invasive pneumococcal disease in Australia, Canada, England & Wales, Israel, and the United States. Infect Dis Ther. 2023 May;12(5):1351-64. doi: 10.1007/s40121-023-00798-x
Guzman-Holst A, Petrozzi V, Velez C, Gupta V, Ochoa TJ, Juliao P. Knowledge, attitudes, and practices concerning maternal immunization among pregnant/postpartum women and health care professionals in Peru. Infect Dis Ther. 2023 Apr;12(4):1151-73. doi: 10.1007/s40121-023-00788-z
Huang L, McDade C, Perdrizet J, Wilson M, Warren S, Nzenze S, Sewdas R. Cost-effectiveness analysis of the South African infant national immunization program for the prevention of pneumococcal disease. Infect Dis Ther. 2023 Mar;12(3):933-50. doi: 10.1007/s40121-023-00767-4
Juliao P, Guzman-Holst A, Gupta V, Velez C, Rosales T, Torres C. Incidence and mortality trends of acute gastroenteritis and pneumococcal disease in children following universal rotavirus and pneumococcal conjugate vaccination in Ecuador. Infect Dis Ther. 2021 Dec;10(4):2593-610. doi: 10.1007/s40121-021-00531-6
Wilson MR, McDade CL, Perdrizet JE, Mignon A, Farkouh RA, Wasserman DM. Validation of a novel forecasting method for estimating the impact of switching pneumococcal conjugate programs: evidence from Belgium. Infect Dis Ther. 2021 Jul 12. doi: 10.1007/s40121-021-00485-9
Sansom SL, Hicks KA, Carrico J, Jacobson EU, Shrestha RK, Green TA, Purcell DW. Optimal allocation of societal HIV prevention resources to reduce HIV incidence in the United States. Am J Public Health. 2021 Jan;111(1):150-8. doi: 10.2105/AJPH.2020.305965
Wilson MR, Wasserman MD, Breton MC, Peloquin F, Earnshaw SR, McDade C, Sings HL, Farkouh RA. Health and economic impact of routine pediatric pneumococcal immunization programs in Canada: a retrospective analysis. Infect Dis Ther. 2020 Aug;9(2):341-53. doi: 10.1007/s40121-020-00294-6
Sacco P, Myers K, Poulos C, Sweeney C, Hollis K, Snow V, Vietri JT. Preferences for adult pneumococcal vaccine recommendations among United States health care providers. Infect Dis Ther. 2019 Dec;8(4):657-70. doi: 10.1007/s40121-019-00266-5
Stull K, Esterberg E, Ajmera M, Candrilli S, Kitt TM, Spalding JR, Patel VP. Use of antifungals and outcomes among inpatients at risk of invasive aspergillosis or mucormycosis in the USA: a retrospective cohort study. Infect Dis Ther. 2019 Dec;8(4):641-55. doi: 10.1007/s40121-019-00267-4
Wasserman MD, Sings HL, Wilson MR, Postma MJ, Breton MC, McDade C, Farkouh RA. Re-analysis of modeling a switch from a 13-valent to 10-valent pneumococcal conjugate vaccine in Canada: leveraging real-world experience from Belgium. Infect Dis Ther. 2019 Mar;8(1):1-3. doi: 10.1007/s40121-018-0222-1
Wilson M, Wasserman M, Jadavi T, Postma M, Breton MC, Peloquin F, Earnshaw S, McDade C, Sings H, Farkouh R. Clinical and economic impact of a potential switch from 13-valent to 10-valent pneumococcal conjugate infant vaccination in Canada. Infect Dis Ther. 2018 Sep;7(3):353-71. doi: 10.1007/s40121-018-0206-1
Parikh RC, McLaurin KK, Margulis AV, Mauskopf J, Ambrose CS, Pavilack M, Candrilli SD. Chronologic age at hospitalization for respiratory syncytial virus among preterm and term infants in the United States. Infect Dis Ther. 2017 Dec;6(4):477-86. doi: 10.1007/s40121-017-0167-9
Lupo PJ, Danysh HE, Symanski E, Langlois PH, Cai Y, Swartz MD. Neighborhood-based socioeconomic position and risk of oral clefts among offspring. Am J Public Health. 2015 Dec;105(12):2518-25. doi: 10.2105/AJPH.2015.302804
Talmud PJ, Stephens JW, Hawe E, Demissie S, Cupples LA, Hurel SJ, Humphries SE, Ordovas JM. The significant increase in cardiovascular disease risk in APOEepsilon4 carriers is evident only in men who smoke: potential relationship between reduced antioxidant status and ApoE4. Ann Hum Genet. 2005;69(6):613-22.
Rothman KJ, Greenland S. Causation and causal inference in epidemiology. Am J Public Health. 2005 Jan 1;95(Suppl 1):S144-150.
Hawe E, Talmud PJ, Miller GJ, Humphries SE, Northwick Park Heart Study . Second Northwick Park Heart Study. Family history is a coronary heart disease risk factor in the Second Northwick Park Heart Study. Ann Hum Genet. 2003;67(Pt 2):97-106.
Talmud PJ, Hawe E, Robertson K, Miller GJ, Miller NE, Humphries SE. Genetic and environmental determinants of plasma high density lipoprotein cholesterol and apolipoprotein AI concentrations in healthy middle-aged men. Ann Hum Genet. 2002;66(Pt 2):111-24.
Bauman KE, Foshee VA, Ennett ST, Pemberton M, Hicks KA, King TS, Koch GG. The influence of a family program on adolescent tobacco and alcohol use. Am J Public Health. 2001 Apr 1;91(4):604-10.
Rothman KJ, Cann CI, Fried MP. Carcinogenicity of dark liquor. Am J Public Health. 1989 Nov;79(11):1516-20.
Flanders WD, Rothman KJ. Occupational risk for laryngeal cancer. Am J Public Health. 1982 Apr 1;72(4):369-72.
Walker AM, Dreyer NA, Friedlander E, Loughlin JE, Rothman KJ, Kohn HI. An independent analysis of the National Cancer Institute study of non-nutritive sweeteners and bladder cancer. Am J Public Health. 1982 Apr;72(4):376-81.
Mackay AM, Rothman KJ. The incidence and severity of burn injuries following Project Burn Prevention. Am J Public Health. 1982 Mar;72(3):248-52.
Jick H, Walker AM, Rothman KJ. The epidemic of endometrial cancer: a commentary. Am J Public Health. 1980 Mar;70(3):264-7.